Media Hub

Highlights: David Khougazian appointed Group Chief Executive Officer to lead Chiesi's next phase of innovation-driven growth, effective 15 October 2026. Bringing over 25 years of international healthcare leadership experience and a strong track record in innovation and transformation, David joins…

HIGHLIGHTS H1 2026 revenues of €1.89 billion, up + 3.6% at CER versus H1 2025, driven by growth in the inhaled triple therapy portfolio and strong momentum in the rare diseases therapeutic area Continued investment in innovation with €426 million invested in R&D (22.5% of sales) Completed strategic…

Key Highlights Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi’s Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed double ICS/LABA combination (inhaled corticosteroid with a long-acting bronchodilator) range have been…

Key Highlights This European Authorisation reinforces Chiesi’s commitment to provide a broad range of formulations and devices to asthma patients. NEXThaler® is a dry powder inhaler (DPI), specifically designed for Chiesi’s extrafine formulations. With the addition of the DPI in the asthma…

PARMA, Italy – June 5, 2026 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that the European Commission (EC) has approved lomitapide capsules for use in children 5…

Parma, Italy and Framingham, Mass., USA – 11 June, 2026 – Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition of KalVista Pharmaceuticals, Inc. (“KalVista”). KalVista is now part of Chiesi Group…

Highlights: Planned transition in the Chair and Vice Chair roles reflects the Chiesi family’s long-term commitment to continuity, shared value and responsible governance across generations Maria Paola Chiesi is appointed Chair, the first woman in this role; aims to reinforce sustainability as an…

Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s…

Highlights: Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs.…

International biopharmaceutical leader accelerates digital transformation with AI-powered customer engagement, unified data, and next-generation integration capabilities APRIL 20, 2026 – Chiesi Group, an international biopharmaceutical group, has selected Salesforce’s Agentforce Life Sciences for…

Parma, 22 September 2026 – Maria Paola Chiesi, Chair of the Board of Chiesi Group, has joined the Chairs of several leading healthcare companies in signing an open letter urging policymakers to consider investment in health and innovation as a strategic priority for Europe's future competitiveness,…

Chiesi Farmaceutici has announced a strategic partnership with Abdi İbrahim to implement a new operating model for Chiesi’s business in Türkiye. Effective 1 October 2026, the partnership will combine Chiesi's global scientific expertise, innovative portfolio and high-quality standards with Abdi…

Following Chiesi's evaluation of the seralutinib development program and the PROSERA Phase 3 study results, Chiesi and Gossamer Bio have agreed to terminate their Collaboration and License Agreement related to the development and commercialization of seralutinib for the treatment of patients with…

Chiesi today announces MHRA approval in the UK of Clenil Modulite (beclometasone; 100mcg and 200mcg) formulated with a non-PFAS, low-GWP, next generation propellant (HFA-152a). These are the first pMDIs to use HFA-152a worldwide, with the UK being the first country to approve these products.…

Chiesi Group and Oak Hill Bio Holdings have announced the completion of patient enrollment in the Phase 2b FOOTPRINTS study evaluating OHB-607 for the prevention of bronchopulmonary dysplasia (BPD), a leading cause of chronic lung disease in premature infants for which there are currently no…

Parma, Italy – 18 May 2026 Chiesi announces that the U.S. Food and Drug Administration (FDA) has approved its single-inhaler triple therapy (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate; BDP/FF/G ) for the maintenance treatment of asthma in adults. The approval was supported by two…

Gossamer Bio released today the topline results from the Phase 3 PROSERA clinical study evaluating seralutinib, an investigational inhaled therapy, in people living with pulmonary arterial hypertension (PAH). Gossamer Bio and Chiesi are jointly developing seralutinib under a global collaboration…

Parma, Italy – 18 December 2025 Chiesi announces the submission of the Carbon Minimal pressurised metered-dose inhaler (pMDI) containing beclometasone in 100 mcg and 200 mcg strengths to the UK Medicines and Healthcare products Regulatory Agency (MHRA) on 5 th December 2025. This submission is part…

Chiesi Group today announced its decision to conclude all clinical trials for the tanimilast program in Chronic Obstructive Pulmonary Disease (COPD) and asthma. This decision follows the full analysis of the Phase 3 PILASTER Main Cohort study in COPD, which did not meet its primary and key secondary…

Chiesi Group today announced the results of the tanimilast Phase III PILASTER clinical study in Chronic obstructive pulmonary disease (COPD). The study did not meet its primary and secondary endpoints. There were no safety signals observed during the study. The company would like to thank the…